Navigation Links
Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
Date:2/22/2010

EMERYVILLE, Calif., Feb. 22 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and H5N1) virus, including three strains of amantadine resistant pandemic H1N1 and two strains of oseltamivir resistant seasonal H1N1.

The results of this study have been published in PLoS One under the title: Triple Combination of Amantadine, Ribavirin, and Oseltamivir is Highly Active and Synergistic Against Drug Resistant Influenza Virus Strains In Vitro. PLoS One is an interactive open-access journal for the communication of all peer-reviewed scientific and medical research published by the Public Library of Science (PLoS). Interested parties may view the article on the PLoS website under Presentations and Publications.

The data demonstrated that amantadine, ribavirin and oseltamivir, when administered as components of a triple combination therapy, had a synergistic effect (i.e. enhanced antiviral activity) against multiple amantadine- and oseltamivir-resistant virus strains.  The data also demonstrated that the antiviral activity of the TCAD regimen is greater than the antiviral activity of any double combination.  Further, when investigating amantadine-resistant virus strains against which amantadine had no significant antiviral activity as a single agent, the addition of amantadine at clinically relevant concentrations to the combination of ribavirin and oseltamivir resulted in a dose dependent inhibition of virus replication. This was similarly observed for oseltamivir in strains that were oseltamivir resistant.  These data demonstrate that the TCAD therapy may have broad-spectrum activity against the circulating resistant influenza A strains, including novel influenza A/H1N1, the pandemic influenza strain.

"Given the fact that the majority of influenza A viruses are resistant to at least one antiviral, these data suggest the advantage of a triple combination drug therapy approach over double combinations or monotherapy," said Gregory Went, Ph.D., chief executive officer and chairman of Adamas.  "We are encouraged about the potency of TCAD therapy measured in preclinical studies and look forward to continued validation of TCAD therapy with our academic and clinical partners."

About TCAD

Adamas is pioneering triple combination antiviral drug (TCAD) therapy for influenza, which is designed to inhibit viral replication at multiple points in the virus proliferation pathway.  TCAD therapy includes Adamas' investigational proprietary fixed-dose combination of amantadine and ribavirin, to be administered adjunctively with a neuraminidase inhibitor such as Tamiflu ® (oseltamivir phosphate, Roche).  Preclinical data indicate that the in vitro combination of these drugs, each with their own mechanism of action, act synergistically to provide a much higher level of antiviral activity than single or double drug combination therapies.  In in vitro studies to date, TCAD therapy also has been found to provide greater antiviral activity across multiple strains of influenza, even those resistant to single pharmaceutical agents. TCAD therapy for influenza A is currently being investigated in a Phase 2 human clinical study.

About Adamas

Adamas is an emerging pharmaceutical company focused on developing small molecule Advantaged Therapeutics to treat neurological and infectious diseases, including influenza A, the cause of the current flu pandemic.  Adamas' approach to pharmaceutical development is to identify synergistic drug mechanisms that can be developed as optimized combination drug therapies to increase safety, efficacy and compliance, thus improving upon the standard of care. Adamas is headquartered in Emeryville, California, with operations in Bangalore, India.  For more information about Adamas, please visit www.adamaspharma.com.  

SOURCE Adamas Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.adamaspharma.com

'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
2. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
3. Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks
4. Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
5. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
6. Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
7. Transdel Pharmaceuticals Announces Management Reorganization
8. Merz Pharmaceuticals Introduces New Mederma(R) Stretch Marks Therapy Now Available in Drugstores Nationwide
9. GlaxoSmithKline President of North America Pharmaceuticals, Deirdre Connelly, Named 2010 Woman of the Year by the Healthcare Businesswomens Association
10. Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
11. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
Breaking Medicine News(10 mins):